Literature DB >> 28189263

Renal complications of immune checkpoint blockade.

Naoka Murakami1, Shveta Motwani2, Leonardo V Riella3.   

Abstract

Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal complications in use of these agents are not very common compared with other immune-related adverse events (irAE). However, it is crucial for physicians to recognize and manage renal manifestations of irAE. In this review, we will summarize the up-to-date knowledge of the clinical presentation, pathologic features, and management of renal irAE. In addition, we will discuss the safety of immune checkpoint inhibitors in patients with chronic kidney disease as well as in kidney transplant recipients.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CTLA-4; Immune check point inhibitor; PD-1; acute kidney injury; chronic kidney injury; transplant

Mesh：

Substances：

Year:  2016        PMID： 28189263      PMCID： PMC5440194          DOI： 10.1016/j.currproblcancer.2016.12.004

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


  55 in total

1.  Anti-CTLA4 antibody-induced lupus nephritis.

Authors:  Fouad Fadel; Khalil El Karoui; Bertrand Knebelmann
Journal:  N Engl J Med       Date:  2009-07-09       Impact factor: 91.245

Review 2.  Co-inhibitory pathways and their importance in immune regulation.

Authors:  Naoka Murakami; Leonardo V Riella
Journal:  Transplantation       Date:  2014-07-15       Impact factor: 4.939

3.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Authors:  Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

4.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

5.  Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.

Authors:  Jeffrey S Weber; Reinhard Dummer; Veerle de Pril; Celeste Lebbé; F Stephen Hodi
Journal:  Cancer       Date:  2013-02-07       Impact factor: 6.860

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Ipilimumab granulomatous interstitial nephritis.

Authors:  Bijin Thajudeen; Machaiah Madhrira; Erika Bracamonte; Lee D Cranmer
Journal:  Am J Ther       Date:  2015 May-Jun       Impact factor: 2.688

8.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

9.  Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma.

Authors:  Naoka Murakami; Thiago J Borges; Michifumi Yamashita; Leonardo V Riella
Journal:  Clin Kidney J       Date:  2016-05-04

10.  CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms.

Authors:  Wataru Ise; Masako Kohyama; Katherine M Nutsch; Hyang Mi Lee; Anish Suri; Emil R Unanue; Theresa L Murphy; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2009-12-27       Impact factor: 25.606
View more
  33 in total

Review 1.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

Authors:  Mark A Perazella; Anushree C Shirali
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

2.  SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).

Authors:  M Majem; E García-Martínez; M Martinez; E Muñoz-Couselo; D Rodriguez-Abreu; R Alvarez; A Arance; A Berrocal; L de la Cruz-Merino; J A Lopez-Martin
Journal:  Clin Transl Oncol       Date:  2020-01-28       Impact factor: 3.405

3.  Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.

Authors:  Hengcheng Zhang; Zijie Wang; Jiayi Zhang; Zeping Gui; Zhijian Han; Jun Tao; Hao Chen; Li Sun; Shuang Fei; Haiwei Yang; Ruoyun Tan; Anil Chandraker; Min Gu
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

Review 4.  Renal Toxicity.

Authors:  Maen Abdelrahim; Ala Abudayyeh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Immune checkpoint inhibitors-induced nephropathy: a French national survey.

Authors:  Marine Andreani; Audrey Fresse; Alexandre O Gérard; Nadège Parassol; Marine Muzzone; Sylvine Pinel; Delphine Bourneau-Martin; Delphine Borchiellini; Fanny Rocher; Vincent L M Esnault; Milou-Daniel Drici
Journal:  Cancer Immunol Immunother       Date:  2021-06-21       Impact factor: 6.968

6.  ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab.

Authors:  Meral Uner; Bassam Alhasson; Jagdeep Obhrai; Serena M Bagnasco
Journal:  Virchows Arch       Date:  2020-07-21       Impact factor: 4.064

Review 7.  Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.

Authors:  Bruno Sangro; Stephen L Chan; Tim Meyer; María Reig; Anthony El-Khoueiry; Peter R Galle
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

8.  The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.

Authors:  Harish Seethapathy; Sophia Zhao; Donald F Chute; Leyre Zubiri; Yaa Oppong; Ian Strohbehn; Frank B Cortazar; David E Leaf; Meghan J Mooradian; Alexandra-Chloé Villani; Ryan J Sullivan; Kerry Reynolds; Meghan E Sise
Journal:  Clin J Am Soc Nephrol       Date:  2019-10-31       Impact factor: 8.237

9.  Non-invasive Detection of Immunotherapy-Induced Adverse Events.

Authors:  Carolina A Ferreira; Pedram Heidari; Bahar Ataeinia; Nicoleta Sinevici; Meghan E Sise; Robert B Colvin; Eric Wehrenberg-Klee; Umar Mahmood
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

Review 10.  Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography.

Authors:  Mark A Anderson; Vikram Kurra; William Bradley; Aoife Kilcoyne; Amirkasra Mojtahed; Susanna I Lee
Journal:  Br J Radiol       Date:  2020-10-28       Impact factor: 3.039
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.